We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders.
- Authors
Mulligan, Stephen P.; Ward, Christopher M.; Whalley, David; Hilmer, Sarah N.
- Abstract
The authors comments on a study on atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy used to manage chronic lymphocytic leukaemia and lymphoproliferative disorders, published in the journal. Topics include use of inhibitor of the Bruton Tyrosine Kinase (BTK) molecule in management of chronic lymphocytic leukaemia (CLL); finding inferring occurrence of atrial fibrillation (AF) associated with ibrutinib; and challenges facing management CLL, and AF.
- Subjects
ATRIAL fibrillation treatment; ATRIAL fibrillation risk factors; ANTICOAGULANTS; LYMPHOCYTIC leukemia; LYMPHOPROLIFERATIVE disorders
- Publication
British Journal of Haematology, 2016, Vol 175, Issue 3, p359
- ISSN
0007-1048
- Publication type
Editorial
- DOI
10.1111/bjh.14321